Millions of open heart surgeries and over 500,000 coronary artery bypass (CPB) surgeries are performed every year. During CPB, blood is routed away from the patient as the surgeon performs Coronary Artery Bypass Grafting (CABG). Complications can occur during this process including significant systemic inflammatory response syndrome (SIRS) which produces a complex and intense "inflammatory" response that can lead to long-lasting cardiac, pulmonary, renal, and neurologic dysfunction in a subset (2-5%) of patients. The US's restriction of a drug, Trasylol®, designed to control CPB bleeding complications in the US made the bleeding and inflammatory-mediated complications as a result of CPB an unmet medical need.
Both NM8074 and NM8070 are capable of blocking the systemic inflammatory response due to cardiopulmonary bypass and/or stenting procedure.